EN DE

Bamboos Health Care Holdings Ltd (2293) Fair Value & Analysis

Industrials · HK · Market cap HK$150M

BH Bamboos Health Care Holdings Ltd 2293 · HK
PriceHK$0.3700
Fair ValueHK$0.8900
Upside+140.5%
Quality66/100
Watch Bamboos Health Care Holdings Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Highly profitable · 23.7% net margin
generates free cash flow
4.00% dividend yield
Ranks above peers (10/13)
Moderate moat 60/100
Evidence: High Range HK$0.6500 – HK$1.12 Share as image

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 3 days ago

Share price −7.5% over the past month.

A solid business, screening 141% undervalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price is below even our cautious bear case (HK$0.6500). The market is more pessimistic than our downside scenario.
  • Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$0.8552 HK$0.3600 Fair Value HK$0.8900 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.3600 – HK$0.8552 · fair‑value band HK$0.6500 – HK$1.12 · the HK$0.3700 price screens below the HK$0.8900 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bamboos Health Care Holdings Ltd (2293) currently trades at HK$0.3700, while our model-based Fair Value estimate is HK$0.8900, implying the stock looks roughly 140.5% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Bamboos Health Care Holdings Ltd generated revenue of HK$70.4M at a net margin of 23.7%. Revenue declined 11.4% year over year. It earns a return on equity of 7.0%. Net debt stands at HK$18.6M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.6500 (bear case) to HK$1.12 (bull case); at HK$0.3700, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at 21% fair-value upside, at 141%, 2293 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income HK$0.4300 HK$0.4500 HK$0.4500 76
Growth DCF HK$0.8000 HK$0.9900 HK$1.19 72
Gordon GGM HK$0.3500 HK$0.5100 HK$0.6600 70
All 24 models by family
DCF Models
FCF DCF HK$0.7900 HK$1.00 HK$1.23 38
5Y Revenue Exit HK$0.6200 HK$0.8000 HK$1.01 39
5Y EBITDA Exit HK$0.8100 HK$1.14 HK$1.50 41
5Y P/E Exit HK$0.7600 HK$1.05 HK$1.34 38
10Y Revenue Exit HK$0.6800 HK$0.8400 HK$1.03 36
10Y EBITDA Exit HK$0.8000 HK$1.04 HK$1.33 37
10Y P/E Exit HK$0.7700 HK$0.9900 HK$1.24 35
Earnings-Based
Graham-Dodd HK$0.3000 HK$0.6900 HK$0.8900 54
PEG = 1.0 HK$0.1200 HK$0.1700 HK$0.2200 46
EPV HK$0.4100 HK$0.4500 HK$0.4800 59
Dividend Discount
Gordon GGM HK$0.3500 HK$0.5100 HK$0.6600 70
DDM Multi-Stage HK$0.3500 HK$0.4700 HK$0.5800 61
Multiples
P/E Multiple HK$0.7200 HK$0.9600 HK$1.20 63
P/S Multiple HK$0.4900 HK$0.6500 HK$0.8100 58
P/B Multiple HK$0.5600 HK$0.7400 HK$0.9300 55
EV/EBIT HK$0.8100 HK$1.04 HK$1.27 53
EV/EBITDA HK$0.9300 HK$1.20 HK$1.47 54
EV/Revenue HK$0.5000 HK$0.6700 HK$0.8300 43
Asset-Based
NCAV (Graham) HK$0.2900 HK$0.3800 HK$0.5700 50
Growth DCF
Growth DCF HK$0.8000 HK$0.9900 HK$1.19 72
Rev-Margin DCF HK$0.6200 HK$0.8100 HK$1.02 67
Economic Profit
Residual Income HK$0.4300 HK$0.4500 HK$0.4500 76
ROIC Compounder HK$0.4100 HK$0.4500 HK$0.4800 67
Growth Earnings
Growth-Adj P/E HK$0.5400 HK$0.7800 HK$1.01 68

Widest divergence: DCF Models (HK$1.00) versus Asset-Based (HK$0.3800). Highest evidence: Residual Income (76).

Notify me when 2293 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$70.4M
Revenue growth (YoY) -11.4%
Net margin 23.7%
Return on equity 7.0%
Free cash flow HK$35.0M FY2025
P/E ratio 9.3
More key figures
Operating margin 21.5%
EPS (TTM) HK$0.0400
Dividend yield 4.0%
EPS growth (YoY) -8.1%
Net debt HK$18.6M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 65 · Market factors (momentum, volatility) 28

Profitability 40
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 64
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 80
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solutions in Hong Kong.

Full company description

Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solutions in Hong Kong. The company offers outreach case assessment; clinic; private nursing; home care and out-patient escorting; professional home care and rehabilitation assessment; palliative/hospice care at home; home safety assessment and modification; professional rehabilitation equipment rental; and physiotherapy and occupational therapy services. It also provides marketing and consulting services; and technology promotion and application services. In addition, the company engages in the sale of health-related merchandise; planning and organizing special events; retail business; and operation of vaccination centers. It serves individuals and institutional clients, including hospitals, social service organizations, and clinics. Bamboos Health Care Holdings Limited was founded in 2009 and is headquartered in Mong Kok, Hong Kong. Bamboos Health Care Holdings Limited is a subsidiary of Gold Empress Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bamboos Health Care Holdings Ltd reported revenue of HK$74.4M in FY2025 versus HK$110M in FY2021, a compound −9.2%/yr. Reported net income was HK$17.5M in FY2025, compounding −26.8%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$74.4M
Latest YoY
−21.5%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−19.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.6%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.7%
Revenue −9.2%/yr
FY21 HK$110M
FY22 HK$140M
FY23 HK$127M
FY24 HK$94.8M
FY25 HK$74.4M
Net income −26.8%/yr
FY21 HK$61.0M
FY22 HK$58.6M
FY23 HK$46.9M
FY24 HK$30.9M
FY25 HK$17.5M
Character of growth · EPS growth decomposed (2014-2025) +4.6 % p.a.
Revenue per share +7.7 pp

of which total revenue +8.8 pp · buybacks/dilution −1.1 pp

EBIT margin −3.9 pp
Tax rate +0.0 pp
Residual (interest, one-offs) +0.9 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 2293: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Bamboos Health Care Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2293

Peer Group

Staffing & Employment Services · 85 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +141% · Top 25%
Return on equity (TTM) 7% · Below median
Return on assets 3% · Above median
Net margin (TTM) 24% · Top 25%
Operating margin (TTM) 21% · Top 25%
Revenue growth -11% · Bottom 25%
Dividend yield (TTM) 4.0% · Above median

Valuation Multiples vs Staffing & Employment Services median · lower = cheaper

P/E (TTM) 9.3× · Cheaper than 75% of peers
P/B 0.65× · Cheaper than 75% of peers
P/S (TTM) 2.13× · Pricier than 75% of peers
P/FCF 0.5× · Cheaper than 75% of peers
EV/EBITDA 5.5× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 43
FUTURE 0 · sector 1
PAST 28 · sector 36
HEALTH 0 · sector 95
DIVIDEND 80 · sector 69

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Staffing & Employment Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Adecco Group ADEN CHF 23.14 CHF 24.08 +4%
Korn Ferry, KFY $83.30 $114.56 +38%
Robert Half Inc RHI $41.55 $20.51 -51%
TriNet Group TNET $66.83 $97.07 +45%
ManpowerGroup Inc MAN $56.22 $23.19 -59%
Insperity, Inc NSP $50.39 $17.34 -66%
FESCO Group 600861 ¥13.17 ¥45.46 +245%
Grupa Pracuj S.A GPP 55.50 PLN 65.45 PLN +18%
Barrett Business Services, Inc BBSI $31.39 $38.11 +21%
Maharah for Human Resources Company 1831 5.36 SAR 6.87 SAR +28%

Compare Bamboos Health Care Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Bamboos Health Care Holdings Ltd (2293) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$0.3700, about +141% (undervalued).
What is the fair value of 2293?
Our model-based fair value for Bamboos Health Care Holdings Ltd is HK$0.8900 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.3700.
What is the quality score of 2293?
Bamboos Health Care Holdings Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Bamboos Health Care Holdings Ltd (2293)?
Bamboos Health Care Holdings Ltd reported trailing-twelve-month revenue of about HK$70.4M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 2293?
The net profit margin of Bamboos Health Care Holdings Ltd is about 23.7%, meaning it keeps roughly 23.7% of revenue as net income. Based on the latest reported figures.
Does Bamboos Health Care Holdings Ltd pay a dividend?
Bamboos Health Care Holdings Ltd currently shows a dividend yield of about 4.00% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Bamboos Health Care Holdings Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.